Sacco RL, Boden-Albala B, Gan R.
et al. Stroke incidence among white, black and Hispanic residents of an urban
community: the Northern Manhattan Stroke Study. Am J Epidemiol.1998;147:259-268.
Broderick J, Brott T, Kothari R.
et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary
first-ever and total incidence rates of stroke among blacks. Stroke.1998;29:415-421.
Broderick JP, Brott T, Tomsick T, Huster G, Miller R. The risk of subarachnoid and intracerebral hemorrhage in blacks as
compared with whites. N Engl J Med.1992;326:733-736.
Morgenstern LB, Spears WD. A triethnic eomparison of intracerbral hemorrhage mortality in Texas. Ann Neurol.1997;42:919-923.
Gillum RF. Stroke mortality in blacks: disturbing trends. Stroke.1999;30:1711-1715.
Giles WH, Kittner SJ, Hebel JR, Losconczy KG, Sherwin RW. Determinants of black-white differences in the risk of cerebral infarction:
the National Health and Nutrition Examination Survey Epidemiologic Follow-up
Study. Arch Intern Med.1995;155:1319-1324.
Friday G, Lai SM, Alter MA.
et al. Stroke in the Lehigh Valley: racial/ethnic differences. Neurology.1989;39:1165-1168.
Gorelick PB. Cerebrovascular disease in African Americans. Stroke.1998;29:2656-2664.
Gornick ME, Eggers PW, Reilly TW.
et al. Effects of race and income on mortality and use of services among Medicare
beneficiaries. N Engl J Med.1996;335:791-799.
Carlise DM, Leake BD, Shaparo MF. Racial and ethnic disparities in the use of cardiovascular procedures:
associations with type of health insurance. Am J Public Health.1997;87:263-267.
Horner RD, Oddone EZ, Matchar DB. Theories explaining racial differences in the utilization of diagnostic
and therapeutic procedures for cerebrovascular disease. Milbank Q.1995;73:443-462.
Harris Y, Gorelick PB, Samuels P, Bempong I. Why African Americans may not be participating in clinical trials. J Natl Med Assoc.1996;88:630-634.
Ford Lynch G, Leurgans SL, Raman R, Barboi A, Gorelick PB. A comparison of stroke risk factors in patients enrolled in stroke
prevention trials. J Natl Med Assoc.2001;93:79-86.
Hass WK, Easton JD, Adams HP.
et al. A randomized trial comparing ticlopidine hydrochloride with aspirin
for the prevention of stroke in high-risk patients. N Engl J Med.1989;321:501-507.
Weisberg LA.for the Ticlopidine Aspirin Stroke Study Group. The efficacy and safety of ticlopidine and aspirin in non-whites: analysis
of a patient subgroup from the Ticlopidine Aspirin Stroke Study. Neurology.1993;43:27-31.
Gorelick PB, Leurgans S, Richardson D, Harris Y, Billingsley M.and the AAASPS Investigators. African American Antiplatelet Stroke Prevention Study: clinical trial
design. J Stroke Cerebrovascular Dis.1998;7:426-434.
Begg C, Cho M, Eastwood S.
et al. Improving the quality of reporting of randomized controlled trials:
the CONSORT statement. JAMA.1996;276:637-639.
Rennie D. How to report randomized controlled trials: the CONSORT statement. JAMA.1996;276:649.
Gorelick PB, Richardson D, Hudson E.
et al. Establishing a community network for recruitment of African Americans
into a clinical trial: the African American Antiplatelet Stroke Prevention
Study (AAASPS) experience. J Natl Med Assoc.1996;88:701-704.
Gorelick PB, Harris Y, Burnett B.
et al. The recruitment triangle: reasons why African Americans enroll, refuse
to enroll, or voluntarily withdraw from a clinical trial: an interim report
from the African American Antiplatelet Stroke Prevention Study (AAASPS). J Natl Med Assoc.1998;90:141-145.
The Publications Committee for the Trial of ORG 10172 in Acute Stroke
Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome
after acute ischemic stroke: a randomized controlled trial. JAMA.1998;279:1265-1272.
Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med.1995;332:238-248.
Krischer JP, Hurley C, Mohan P.
et al. An automated patient registration and treatment randomization system
for multi-center trials. Control Clin Trials.1991;12:367-377.
Kim K, DeMets D. Group sequential monitoring in clinical trials. J Am Stat Assoc.1987;74:149-154.
Richardson D, Leurgans S. Sample size justification in phase III/IV clinical trials. Neuroepidemiology.1998;17:63-66.
Cox DR. Regression models and life tables. J R Stat Soc.1972;34:187-220.
Teitelbaum P. Pharmacodynamics and pharmacokinetics of ticlopidine. In: Hass WK, Easton JD, eds. Ticlopidine, Platelets
and Vascular Disease. New York, NY: Springer-Verlag; 1993:27-40.
Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med.1998;129:394-405.
Gent M, Blakely JA, Easton JD.
et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet.1989;1:1215-1220.
CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus Aspirin in Patients
at Risk of Ischemic Events (CAPRIE). Lancet.1996;348:1329-1339.
Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized
pharmaceutical treatment. J Natl Med Assoc.2002;94(suppl):1-26.
Mohr JP, Thompson JLP, Lazar RM.
et al. A comparison of warfarin and aspirin for the prevention of recurrent
ischemic stroke. N Engl J Med.2001;345:1444-1451.
Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy,
I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet
therapy in various categories of patients. BMJ.1994;308:81-106.
Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K.
et al. Thrombotic thrombocytopenia purpura associated with ticlopidine: a
review of 60 cases. Ann Intern Med.1998;128:541-544.
Bennett CL, Kiss JE, Weinberg PD.
et al. Thrombotic thrombocytopenia purpura after stenting and ticlopidine. Lancet.1998;352:1036-1037.
Steinhubl SR, Tan WA, Foody JM, Topol EJ.for the EPISTENT Investigators. Incidence and clinical course of thrombotic thrombocytopenia purpura
due to ticlopidine following coronary stenting. JAMA.1999;281:806-810.
Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic
acid in the secondary prevention of stroke. J Neurol Sci.1996;143:1-13.
Chen ZM, Sandercock P, Pan HC.
et al. Indications for early aspirin use in acute ischemic stroke: a combined
analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial
and the International Stroke Trial. Stroke.2000;31:1240-1249.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy
for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ.2002;324:71-86.
Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest.2001;119:300S-320S.
Wolf PA, Clagett GP, Easton JD.
et al. Preventing ischemic stroke in patients with prior stroke and transient
ischemic attack: a statement for healthcare professionals from the Stroke
Council of the American Heart Association. Stroke.1999;30:1991-1994.
Hankey GJ, Sudlow CLM, Dunbabin DW. Thienopyridines or aspirin to prevent stroke and other serious vascular
events in patients at high risk of vascular disease? a systematic review of
the evidence from randomized trials. Stroke.2000;31:1779-1784.
Warlow C. Aspirin should be the first-line antiplatelet therapy in the secondary
prevention of stroke. Stroke.2002;33:2137-2138.
Powers WJ. Oral anticoagulation therapy for the prevention of stroke. N Engl J Med.2001;345:1493-1495.